CIK 0001372299 · Non-accelerated filer<br>Smaller reporting company
Ocugen, Inc.
Sign in to watch- Ticker
- OCGN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 484-328-4701
- Business address
- 11 GREAT VALLEY PARKWAY, MALVERN, PA, 19355
- Former names
- HISTOGENICS CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,088,801
- in 2 filings, $1.1M under 10b5-1 plans
Net −$1,088,801. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-18 | Crespo Jessica CAO/SVP, Finance | Grant or award | +22,940 | 40,440 | ||
| 2022-03-18 | Crespo Jessica CAO/SVP, Finance | Grant or award · Option (Right to Buy) | +84,192 | 84,192 | ||
| 2022-03-16 | Musunuri Shankar Chief Executive Officer | Option exercise | +81,823 | $0.33 | $27K | 834,363 |
| 2022-03-16 | Musunuri Shankar Chief Executive Officer | Sale | −81,823 | $2.65 | $217K | 752,540 |
| 2022-03-16 | Musunuri Shankar Chief Executive Officer | Option exercise · Option (Right to Buy) | −81,823 | 904,764 | ||
| 2022-03-03 | Zhang Junge Director | Option exercise | +39,000 | $0.51 | $20K | 39,000 |
| 2022-03-03 | Zhang Junge Director | Option exercise | +49,000 | $1.83 | $90K | 88,000 |
| 2022-03-03 | Zhang Junge Director | Option exercise · Option (Right to Buy) | +39,000 | 15,000 | ||
| 2022-03-03 | Zhang Junge Director | Option exercise · Option (Right to Buy) | +49,000 | 77,000 | ||
| 2022-02-14 | Musunuri Shankar Chief Executive Officer | Option exercise | +90,000 | $0.33 | $30K | 842,540 |
| 2022-02-14 | Musunuri Shankar Chief Executive Officer | Sale | −90,000 | $3.74 | $337K | 752,540 |
| 2022-02-14 | Musunuri Shankar Chief Executive Officer | Option exercise · Option (Right to Buy) | −90,000 | 986,587 | ||
| 2022-01-18 | Kumar Ramesh Director | Option exercise | +7,500 | $0.51 | $4K | 7,500 |
| 2022-01-18 | Kumar Ramesh Director | Sale | −7,500 | $4.07 | $31K | 0 |
| 2022-01-18 | Kumar Ramesh Director | Option exercise · Option (Right to Buy) | +7,500 | 24,000 | ||
| 2022-01-03 | Subramanian Sanjay Chief Financial Officer | Grant or award | +125,534 | 161,125 | ||
| 2022-01-03 | Subramanian Sanjay Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +454,007 | 454,007 | ||
| 2022-01-03 | Musunuri Shankar Chief Executive Officer | Grant or award | +346,540 | 752,540 | ||
| 2022-01-03 | Musunuri Shankar Chief Executive Officer | Grant or award · Option (Right to Buy) | +1,253,299 | 1,253,299 | ||
| 2021-12-16 | Subramanian Sanjay Chief Financial Officer | Grant or award · Option(Right toBuy) | +35,560 | 71,120 |
Page 6 of 27 · 525 trades